The phase II CheckMate7A8 (NCT04075604) (67) and phase III CheckMate7FL (NCT04109066) (68) about nivolumab combined with endocrine therapy in the neoadjuvant setting of hormone receptor-positive/HER2-negative breast cancer are enrolling. Here, NR4A1 is linked to breast cancer.